Looking to the entire person when treating patients
View As Webpage

NTT Data
 
HIMSS
 
 

Monday, July 20, 2020

 
 
Dr. Lynae Brayboy
 

Clue's first CMO, Dr. Lynae Brayboy, talks fertility tech, LGBTQ health, the clinical trial gender gap >>

 

BY LAURA LOVETT

Photo credit: Clue Health


Berlin-based Clue Health was one of the early companies in the femtech world. Founded in 2012, to date it has raised just under $30 million. Today it named Dr. Lynae Brayboy its first chief medical officer. 

A trained OBGYN, with a specialty in reproductive endocrinology and fertility, Brayboy has a long history of working in women’s health and a track record of studying femtech products. 


“When I was having my training there was no such thing as femtech, so individuals would come into office hours and have complaints or issues and would have to rely on recollection or misinformation. I think femtech just broadened the reach of healthcare, and it also improves education,” she said. 


Specifically, she said that when it comes to the fertility space, there is a lot of false news floating around, and digital tools could help curb the spread. 


“There’s a lot of bad information on websites. Clue prides itself on providing science-based accurate information and we want to be a trusted source for women,” she said. “I think our position is that we can help alleviate some of that anxiety because of what we offer on our website, and also through our app – and help women feel as though they can ask questions that are informed when they actually go to a specialist or go to a physician, so that they are not spending time – which is very valuable, if you are suffering from infertility – trying to find out information. They can get the information, have a directed conversation with their provider, and then have actual plans afterwards.”


She also noted that, while Clue is often called a femtech product, it caters to anyone with periods or ovaries, and provides specific content for LGBTQ patients. 


“There’s a lot that needs to be addressed with the LGBTQ population in general and it is not being addressed in healthcare like it should be,” she said. “Even when I attend conferences, there will be very few sections about fertility care for those individuals. We are trying to raise awareness so that people can understand that everyone needs fertility care regardless of how they identify.”


While Clue got its start focusing on the reproductive years, Brayboy said that there’s potential in digital tools across a life span.  


“I think the beauty of the field of obstetrics and gynecology is that you take care of girls all the way to women. I think that hopefully in our future we’ll be doing that very same thing and be providing services to young adolescent women as they are making the pubertal transition all the way to women in menopause, which I think is really exciting and hopefully is on the horizon for us.”

 
 

Femtech a help in clinical trial gender gap?

Historically the medical world has had a gender gap in clinical trials. In fact, it wasn’t until 1994 that the U.S. National Institutes of Health mandated that women be included in clinical trials. But Brayboy said she sees digital tools as a way to help remedy this and spread information. 


“I think in general a lot of populations have been left out of research. What does that mean? Well then, you’re not sure if a particular drug or what the efficacy is in women or people with periods. So what Clue could possibly do, and other femtech apps, is raise awareness – raise awareness about certain trials and raise awareness about representation,” she said. “Then we can ensure that people with periods and women are not left out because we are not biologically the same. We really need to understand how things metabolize differently, the side effects and how they can impact early pregnancy.”


She noted that if a clinical trial is sponsored by the U.S. government or the National Institutes of Health, researchers need to submit a type of plan about how they will recruit women or why they have to exclude women. 


“If I wasn’t in this industry how would I find out? How would I even know to sign up? Usually most studies recruit through flyers, maybe some ads. But I think femtech has the ability to really display what things are available and where,” she said. 


Looking ahead, Brayboy said she sees diversity being a big way of shaping the industry, not just in clinical trials, but also in the workforce.


“We are committed to diversity as well,” she said. “The real thing with science is that science is actually not a very diverse place, but on our team, we are a diverse science team not only in terms of training but also racially and in thought processes and background and origin.”


woman holding a cellphone
 

Meaningful digital health engagement is more complicated than how long or often users log in >>

 

BY DAVE MUOIO

Sustained engagement is a key metric when determining whether a digital health-based intervention is finding its mark, but the industry has been anything but uniform in determining objective measures of user behavior and their relationship to clinical outcomes.


A study published Friday in JAMA Network Open takes another approach and employs machine learning techniques to better describe engagement among 54,604 patients provided a digital health intervention – in this case, an internet-based cognitive behavioral therapy (iCBT) tool for depression and anxiety symptoms developed by SilverCloud Health.


"We used machine learning to build a probabilistic graphical modeling framework to understand longitudinal patterns of engagement with iCBT," the study's authors, which included researchers from Microsoft Research Cambridge and SilverCloud Health, wrote. "We hypothesized that these patterns would allow us to infer distinct, heterogeneous patient behavior subtypes. We further hypothesized that these subtypes are associated with the intervention’s success of improving mental health and that different subtypes of engagement are associated with differences in clinical outcomes."


The researchers' cohort comprised of de-identified patient data collected between January 31, 2015 and March 31, 2019 from SilverCloud's Space From Depression and Anxiety treatment program. This intervention included digital journals, quizzes, CBT exercises and live human guidance.


The researchers defined and measured two types of engagement: use of the iCBT program within a given week, and use of one of the 14 sections of the program within a given week. These were reviewed alongside objective screens of depression and anxiety – the Patient Health Questionnaire-9 (PHQ-9) for the former and Generalized Anxiety Disorder-7(GAD-7) for the latter.


Across the cohort, patients spent a mean 111 minutes using the iCBT program and improved their clinical scores for both depression and anxiety symptoms.


By applying the modeling framework to the cohort, the researchers identified five heterogeneous subtypes of engagement: low engagers, late engagers, high engagers with rapid disengagement, high engagers with moderate decrease and very high engagers.


These groups had varying changes in their depression and anxiety symptom scores after the 14-week program. For example, mean depression score decreases were greatest among high engagers with rapid disengagement and actually increased among the late engager group.


WHY IT MATTERS

The researchers highlighted subtype trends suggesting that clinical outcomes were not uniformly proportional to the amount of time patients spent with the intervention, and suggested different types of engagement with the content. For example, the high engagers with moderate decrease group more often used the core modules of the tool such as mood tracking and goal-based activities, whereas the very high engager group were more likely to to use relaxation and mindfulness tools.


"These insights may facilitate tailoring of interventions for specific subtypes of engagement," they wrote. "For example, we may be able to front-load specific recommendations of content associated with improved therapy engagement and clinical outcomes for patients within particular subtypes. Such patterns may elucidate different modalities of engagement that can help us to better triage patients for different therapy modules or activities."


Still, the researcher's metrics and approach may not be telling the full story of meaningful digital health engagement.


In an accompanying commentary, Dr. John Torous of the Beth Israel Deaconness Medical Center and Harvard Medical School, and Erin Michalak and Health O'Brien, both from the University of British Columbia, Vancouver, wrote that it was "encouraging" to see companies objectively evaluating their products and sharing those data publicly. That being said, both the study and digital health at large tend to focus on "blunt" behavioral measures that do little to describe users' affective or cognitive investment with the tool.


"Although it is essential to take a longitudinal perspective with engagement and examine use over time, duration of use itself is not a reliable indicator of engagement," they wrote. "Studies in human-computer interaction have shown that it is difficult to disambiguate negative, frustrating experiences with technology from positive, absorbing ones based on this measure, and that a person’s willingness to return is more telling of engagement. Thus, we might ask whether the user is continuing to come back to the app rather than focusing on their session length and degree of active engagement with different tools."


WHAT'S THE HISTORY?

Poor engagement among users provided a health app or other digital health intervention is a long-standing concern, and often can hamper investigations on whether or not the tool is delivering a clinical benefit. Mental health apps in particular have become something of a Wild West, with many flooding the market without supporting evidence of their efficacy.


 

ADVERTISEMENT

Optum
 

REGULATION

The looming end to the telehealth boom >>

Former U.S. Medicaid CMO Dr. Andrey Ostrovsky outlines how tech entrepreneurs, investors and digital-transformation leaders can impact a legislative fix and enable long-term telehealth access.

 

FUNDING AND IPOS

NowRx's online pharmacy crowdfunds $20M, Activ Surgical closes $15M and more digital health funding news >>

Also: Noteworth's $5 million seed round, Qualio's $11 million Series A and Cohere Health's $10 million Series A.

 

MEDICAL DEVICES

Medtronic to acquire the French implant tech company Medicrea >>

Medtronic says the acquisition means it will be able to offer AI-driven surgical planning, robotic assisted surgery and personalized spinal implants.

 

BIG TECH IN HEALTH

Omron launches UVC disinfection robot targeting COVID-19 virus >>

According to Omron, the robot can get up and running with a simple software integration and does not require modifications or construction of the premises it is used in.

 

AI, DATA AND ANALYTICS

Korea's 'Dr. Answer' to undergo trial in Saudi Arabia >>

The AI medical software solution reportedly identifies abnormalities in body fluids and tissues, and is currently able to diagnose eight diseases, including rare genetic disorders.

 

HIMSS TV

Looking to the entire person when treating patients >>

Equality Health Director of Clinical Outreach Solutions Roger Pena says when treating patients, take into account his or her age, race, gender and ZIP code, as they can have a big impact on patients' overall health.

 

HIMSS INSIGHTS

COVID-19 and Beyond >>

The latest issue in the HIMSS Insights series focuses on the implications of the coronavirus crisis for healthcare and healthcare digitization. Several months into the crisis at the time of publication, we try to identify major trends coming out of COVID-19 and unmet digital needs that are being unmasked. The second area of focus is digital health technology assessment which is arising in several healthcare systems and remains highly relevant during the pandemic and beyond.

 

ADVERTISEMENT

HIMSS Analytics
 
 

Real-time analytics, during the pandemic and beyond >>

 

PUTTING DATA TO WORK

This month, we look at the lasting lessons from the COVID-19 crisis about how data is exchanged, how it's managed, how it's visualized, how it's put to work informing patient care decisions and population health.

Facebook Twitter LinkedIn

MobiHealthNews & HIMSS Media.
Editorial Inquiries | Advertising | Privacy Policy | Unsubscribe

33 West Monroe Street, Suite 1700, Chicago, IL 60603-5616